Olson Eric R 4
4 · Syros Pharmaceuticals, Inc. · Filed Mar 17, 2021
Insider Transaction Report
Form 4
Olson Eric R
Chief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2021-03-15−3,628→ 90,697 totalExercise: $1.01Exp: 2023-05-22→ Common Stock (3,628 underlying) - Exercise/Conversion
Common Stock
2021-03-15$1.01/sh+3,628$3,664→ 3,628 total - Sale
Common Stock
2021-03-15$9.47/sh−3,628$34,372→ 0 total
Footnotes (3)
- [F1]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.07 to $9.66, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]This option is fully vested.